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1703-41 Second Harmonic Imaging Enhances Contrast
Echocardiography in Patients with Cardiac Disease:
Demonstration of Feasibility
Few data are available regarding the relationship between regional wall mo-
tion (RWM) and regional myocardial blood flow (RMBF) in humans with
chronic ischemic heart disease (IHO). This study tests the hypothesis that:
1) at rest, degree of RMW abnormality correlates with level of RMBF and 21
RMBF response to adenosine (Ado) correlates with RWM response to dobu-
tamine stress. RMBF (ml/min/g) was measured by PET (13NH3) at rest and
with Ado (140 /lg/kg/min x 5 min) in 12 patients (Pts) with cath documented
IHO. Each Pt also had rest, low (5 /lglkg/min) and high dose (40 /lglkg/min)
dobutamine echo performed on the day of the PET exam. RMBF (ml/min/g)
by PET in distal, mid and proximal left ventricular short axis slices (8 seg-
ments (segs)/slice) was correlated with RWM by echo in comparable segs.
Rest RMBF in segs with normal RWM In = 135; 12 pts) was similar to that
of hypokinetic (n ~ 79) segs (0.74 ± 0.34 vs 0.68 ± 0.35, respectively; Mean
± SDI but greater (P < 0.005) than that of akinetic segs (0.60 ± 0.40; n =
94). Segs with normal RWM at rest which augmented normally at high dose
dobutamine (n = 116; 11 pts) had higher rest RMBF vs those (n = 19; 9
pts) which became hypo/akinetic (0.77 ± 0.35 vs 0.56 ± 0,22, respectively,
P < 0.02). The absolute increment in RMBF with Ado in segs having normal
RWM at rest and at high dose dobutamine (0.47 ± 0.53 ml/min/g) exceeded
that of segs which became hypo/akinetic 10.16 ± 0.34, P < 0.02). Segs hy-
pokinetic at rest which normalized at low dose dobutamine tended to have
a larger increment in RMBF with Ado 10.57 ± 0.60) versus hypokinetic segs
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Three-dimensional Echocardiographic Delineation of
Myocardial Perfusion Territories: Description of a
New 3-D Image Processing Approach with a New
Ultrasound Contrast Agent
Alain Delabays, Lissa Sugeng, Oi-Ling Cao, Giuseppina Magni, Steven Schwartz,
Natesa Pandian. Tufts-New Engl Med Center, Boston, MA
Previous work dealing with contrast echo evaluation of myocardial perfusion
has relied only on 2-D echo images, which do not provide a comprehen-
sive description of perfusion territories of the whole LV Since every facet
of LV perfusion is multidimensional, 3-dimensional assessment of perfusion
territories would be more relevant clinically. 2 problems have hampered ad-
vances in this area: (1) Lack of image processing algorithms that can auto-
matically segment out regions of contrast enhancement in volume-rendered
30E, and (2) Lack of a stable contrast agent that would show persistent
opacification allowing for acquisition of multiple 20E slices required for 3DE.
In this study we explored the feasibility of defining perfusion territories using
newly developed 3DE segmentation and extraction software and a newer
stable contrast agent FS069. In 8 anesthetized dogs, using a computer-
driven motor, we obtained parallel (1 mm intervals) short-axis images of the
heart, in base-line, and with a small dose of the contrast agent FS069 (MBI)
injected in the aortic root. This process was repeated with administration of
FS069 after occlusion and release of various coronary arterial branches. 30E
was performed from all collected data. Contrast enhancements and perfu-
sion defects persisted long enough for 3DE data acquisition (average 2 min).
FS069 demonstrated excellent contrast enhancement of the LV myocardium
not only in 20E but also in digitally reformatted 30E data matrix. Contrast de-
fects during coronary occlusion were crisply defined as well. In all the 30E
studies, recently developed image processing algorithms allowed extraction
of myocardium alone and exclusion of contrast in the cavity. In addition, use
of various thresholding and opacification schema permitted discrimination
of perfused and non-perfused territories. When viewed against the baseline
30E, hypoperfused regions appeared as gaps of missing myocardial regions.
The hypoperfused regions could be extracted discretely and visualized sepa-
rately in 3D (with retained gray scale data) in dynamicforms from different ori-
entations. We conclude that the advanced 30E image processing approach
and the new generation contrast agent FS069 allow three-dimensional ap-
praisal of myocardial perfusion territories.
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Relationship Between Regional Myocardial Blood
Flow and Regional Wall Motion at Rest and with
Stress in Humans with Chronic Ischemic Heart
Disease
Hal A. Skopicki, Stephen A. Abraham, Neil J. Weissman, Alan J. Fischman,
Nathaniel M. Alpert, Michael H. Picard, Henry Gewirtz. Massachusetts General
Hospital, Boston. MA
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Thomas Porter, Feng Xie, Alan Kricsfeld. University of Nebraska Medical Center,
Omaha, Nebraska
Intravenous IIV) perfluoropropane-enhanced sonicated dextrose albumin
(PESDA) is an ultrasound contrast agent produced by mixing a gas of low
blood solubility and diffusivity with dextrose albumin during sonication. This
agent has produced both improved left ventricular (LV) cavity and myocardial
contrast in animals. Its safety and efficacy in humans has not been deter-
mined. Accordingly, we gave IV doses of PESDA (0.01-002 ml/kg) to seven
humans (4 male, 3 female; mean age 63 ± 14 years). Five had coronary artery
disease, one had aortic stenosis, and one had no evidence of structural heart
disease, Patient symptoms, mean arterial blood pressure (MAP). heart rate
(HR). EKG, respiratory rate (RR) and oxygen saturation (aS) were monitored
before and after each injection. Parasternal short axis, and apical left ven-
tricular views were analyzed during injection to determine myocardial con-
trast produced and degree of endocardial border enhancement, respectively.
Myocardial contrast (MC) was determined by quantifying end-systolic peak
videointensity (PVI) from the parasternal short axis view (PSSAXV)
All patients reported no adverse symptoms during the 0.01 or 0.02 ml/kg
IV injections of PESDA. Hemodynamic and oxygen saturation changes fol-
lowing the 0.02 ml/kg injections are below (all were not significant) (BPM =
beats per minute):
Both the 0.01 and 0.02 mllkg IV PESDA injections produced acoustic shad-
owing (AS) in the LV cavity. The duration of AS in the apical four chamber
view was 60 ± 16 second~. Following this, there was an extended period
of left ventricular cavity contrast at both end-diastole and end-systole for a
mean of 55 ± 29 seconds. Myocardial contrast was quantifiable only from
the anterior wall in the PSSAXV because of the prolonged acoustic shad-
owing of the other myocardial segments. Peak myocardial videointensity in
this region averaged 4.3 ± 1.0 units. We conclude that IV PESDA: (a) is a
safe ultrasound contrast agent in humans; (b) produces an extended period
of LV cavity contrast in both diastole and systole, and (c) in very low doses
produces prolonged cavity attenuation which prevents the detection of my-
ocardial contrast.
Ehtisham Mahmud, Bruno Cotter, Bruce Kimura, Constance Calisi, Oi Ling Kwan,
Linda Donaghey, Karen Wheeler, Daniel Blanchard, William Keen, Anthony
N. DeMaria. University of California at San Diego, CA
The fact that contrast microbubbles suspended in blood resonate results in
the ability to alter the frequency of sound energy reflected by these targets.
Therefore, preferential recording of reflected energy at frequencies which
are harmonics of the carrier frequency offers the potential to selectively en-
hance contrast signals. We tested the clinical value of this concept during
standard transthoracic echocardiography in 5 pts with organic heart disease
(CAD, cardiomyopathy, other). Echo imaging was performed in the apical 4-
chamber view using a prototype instrument engineered to perform imaging
focused about 2.5 or 5.0 megaHertz. Contrast signals were produced by in-
jecting 3000-4000 mg of SHU508 (Levovist) into the brachial vein. For each
injection, images were obtained at both 2.5 MHz and its second harmonic.
Pts tolerated the injections well without change in BP or heart rate. Contrast
echoes were analyzed qualitatively (1 + weak and incomplete opacification,
2+ complete LV filling, 3+ dense and complete filling) and with videointen-
sity measurements. All pts manifested 1+ opacification during regular imag-
ing except for one who showed no LV contrast. With 2nd harmonic imag-
ing all pts were judged to have 2+ signals. Analysis of the ratio of LV cav-
ity to myocardial intensity (gray levels) revealed a ratio of 0.7 ± 0.09 with
regular imaging and 5.0 ± 2 with 2nd harmonics. Thus, second harmonic
imaging can substantially enhance the relative signal from microbubbles as
compared to tissue in patients with cardiac disease. This selective contrast
amplification enables more dense and complete opacification of the LV Sec-
ond harmonic imaging should prove of value in the clinical application of
contrast echocardiography.
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